Investigating glutaminolysis as a treatment target for T-ALL
The role of glutaminolysis as a therapeutic target in T-ALL
['FUNDING_R01'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-10663181
This study is looking at how a process called glutaminolysis affects T-lineage acute lymphoblastic leukemia (T-ALL), a type of blood cancer, to find new ways to make current treatments work better for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-10663181 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how glutaminolysis, a metabolic process, can be targeted to treat T-lineage acute lymphoblastic leukemia (T-ALL), a type of blood cancer. The study explores the effects of inhibiting glutaminolysis both genetically and pharmacologically, aiming to enhance the effectiveness of existing therapies for patients with T-ALL. By examining the role of glutamine in cancer metabolism, the research seeks to uncover mechanisms that contribute to treatment resistance and relapse in patients. The findings could lead to new therapeutic strategies that improve outcomes for individuals affected by this malignancy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with T-lineage acute lymphoblastic leukemia who have experienced relapses or are at risk of refractory disease.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with T-ALL may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options that improve survival rates and reduce relapses in patients with T-ALL.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HERRANZ, DANIEL — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: HERRANZ, DANIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.